- Home
- USIO vs RNTX Comparison
USIO vs RNTX Comparison
Compare USIO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- RNTX
- Stock Information
- Founded
- USIO 1998
- RNTX 2001
- Country
- USIO United States
- RNTX United States
- Employees
- USIO N/A
- RNTX N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- RNTX Health Care
- Exchange
- USIO Nasdaq
- RNTX Nasdaq
- Market Cap
- USIO 37.6M
- RNTX 34.6M
- IPO Year
- USIO N/A
- RNTX N/A
- Fundamental
- Price
- USIO $1.44
- RNTX $1.55
- Analyst Decision
- USIO Strong Buy
- RNTX Buy
- Analyst Count
- USIO 1
- RNTX 2
- Target Price
- USIO $4.00
- RNTX $10.00
- AVG Volume (30 Days)
- USIO 72.5K
- RNTX 156.7K
- Earning Date
- USIO 11-05-2025
- RNTX 11-13-2025
- Dividend Yield
- USIO N/A
- RNTX N/A
- EPS Growth
- USIO N/A
- RNTX N/A
- EPS
- USIO 0.11
- RNTX N/A
- Revenue
- USIO $83,851,606.00
- RNTX N/A
- Revenue This Year
- USIO $8.71
- RNTX N/A
- Revenue Next Year
- USIO $12.48
- RNTX N/A
- P/E Ratio
- USIO $13.28
- RNTX N/A
- Revenue Growth
- USIO 2.05
- RNTX N/A
- 52 Week Low
- USIO $1.24
- RNTX $1.04
- 52 Week High
- USIO $2.92
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- USIO 49.86
- RNTX 63.81
- Support Level
- USIO $1.43
- RNTX $1.30
- Resistance Level
- USIO $1.47
- RNTX $1.52
- Average True Range (ATR)
- USIO 0.05
- RNTX 0.11
- MACD
- USIO 0.01
- RNTX 0.02
- Stochastic Oscillator
- USIO 63.81
- RNTX 97.37
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.